These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 26288226)

  • 41. A randomized pilot study of donor stem cell infusion in living-related kidney transplant recipients receiving alemtuzumab.
    Ciancio G; Sageshima J; Akpinar E; Gaynor JJ; Chen L; Zarak A; Hanson L; Tueros L; Guerra G; Mattiazzi A; Kupin W; Roth D; Ricordi C; Burke GW
    Transplantation; 2013 Nov; 96(9):800-6. PubMed ID: 23903014
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy.
    Tan HP; Kaczorowski DJ; Basu A; Unruh M; McCauley J; Wu C; Donaldson J; Dvorchik I; Kayler L; Marcos A; Randhawa P; Smetanka C; Starzl TE; Shapiro R
    Am J Transplant; 2006 Oct; 6(10):2409-17. PubMed ID: 16889606
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Induction Therapies in Live Donor Kidney Transplantation on Tacrolimus and Mycophenolate With or Without Steroid Maintenance.
    Tanriover B; Zhang S; MacConmara M; Gao A; Sandikci B; Ayvaci MU; Mete M; Tsapepas D; Rajora N; Mohan P; Lakhia R; Lu CY; Vazquez M
    Clin J Am Soc Nephrol; 2015 Jun; 10(6):1041-9. PubMed ID: 25979971
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A randomized trial of alemtuzumab vs. anti-thymocyte globulin induction in renal and pancreas transplantation.
    Farney A; Sundberg A; Moore P; Hartmann E; Rogers J; Doares W; Jarrett A; Adams P; Stratta R
    Clin Transplant; 2008; 22(1):41-9. PubMed ID: 18217904
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Improved efficacy of basiliximab over antilymphocyte globulin induction therapy in paediatric renal transplantation.
    Clark G; Walsh G; Deshpande P; Koffman G
    Nephrol Dial Transplant; 2002 Jul; 17(7):1304-9. PubMed ID: 12105256
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Alemtuzumab with corticosteroid minimization for pediatric deceased donor renal transplantation: a seven-yr experience.
    Supe-Markovina K; Melquist JJ; Connolly D; DiCarlo HN; Waltzer WC; Fine RN; Darras FS
    Pediatr Transplant; 2014 Jun; 18(4):363-8. PubMed ID: 24712738
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Two hundred living donor kidney transplantations under alemtuzumab induction and tacrolimus monotherapy: 3-year follow-up.
    Tan HP; Donaldson J; Basu A; Unruh M; Randhawa P; Sharma V; Morgan C; McCauley J; Wu C; Shah N; Zeevi A; Shapiro R
    Am J Transplant; 2009 Feb; 9(2):355-66. PubMed ID: 19120078
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of prednisone versus no prednisone as part of maintenance immunosuppression on long-term renal transplant function.
    Gallon LG; Winoto J; Leventhal JR; Parker MA; Kaufman DB
    Clin J Am Soc Nephrol; 2006 Sep; 1(5):1029-38. PubMed ID: 17699323
    [TBL] [Abstract][Full Text] [Related]  

  • 49. One-year results of basiliximab induction and tacrolimus associated with sequential steroid and MMF treatment in pediatric kidney transplant recipient.
    Montini G; Murer L; Ghio L; Pietrobon B; Ginevri F; Ferraresso M; Cardillo M; Scalamogna M; Perfumo F; Edefonti A; Zanon GF; Zacchello G
    Transpl Int; 2005 Jan; 18(1):36-42. PubMed ID: 15612981
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Long-term renal transplant function in recipient of simultaneous kidney and pancreas transplant maintained with two prednisone-free maintenance immunosuppressive combinations: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus.
    Gallon LG; Winoto J; Chhabra D; Parker MA; Leventhal JR; Kaufman DB
    Transplantation; 2007 May; 83(10):1324-9. PubMed ID: 17519781
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients.
    Asberg A; Midtvedt K; Line PD; Narverud J; Holdaas H; Jenssen T; Reisaeter AV; Johnsen LF; Fauchald P; Hartmann A
    Transplantation; 2006 Jul; 82(1):62-8. PubMed ID: 16861943
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-term results of pancreas transplantation under tacrolius immunosuppression.
    Jordan ML; Shapiro R; Gritsch HA; Egidi F; Khanna A; Vivas CA; Scantlebury VP; Fung JJ; Starzl TE; Corry RJ
    Transplantation; 1999 Jan; 67(2):266-72. PubMed ID: 10075592
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immunosuppression With CD40 Costimulatory Blockade Plus Rapamycin for Simultaneous Islet-Kidney Transplantation in Nonhuman Primates.
    Oura T; Hotta K; Lei J; Markmann J; Rosales I; Dehnadi A; Kawai K; Ndishabandi D; Smith RN; Cosimi AB; Kawai T
    Am J Transplant; 2017 Mar; 17(3):646-656. PubMed ID: 27501203
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Survival Associated With Sirolimus Plus Tacrolimus Maintenance Without Induction Therapy Compared With Standard Immunosuppression After Lung Transplant.
    Wijesinha M; Hirshon JM; Terrin M; Magder L; Brown C; Stafford K; Iacono A
    JAMA Netw Open; 2019 Aug; 2(8):e1910297. PubMed ID: 31461151
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Early outcomes using alemtuzumab induction in lung transplantation.
    van Loenhout KC; Groves SC; Galazka M; Sherman B; Britt E; Garcia J; Griffith B; Iacono A
    Interact Cardiovasc Thorac Surg; 2010 Feb; 10(2):190-4. PubMed ID: 19939852
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Islet transplantation in type 1 diabetics using an immunosuppressive protocol based on the anti-LFA-1 antibody efalizumab.
    Posselt AM; Bellin MD; Tavakol M; Szot GL; Frassetto LA; Masharani U; Kerlan RK; Fong L; Vincenti FG; Hering BJ; Bluestone JA; Stock PG
    Am J Transplant; 2010 Aug; 10(8):1870-80. PubMed ID: 20659093
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Steroid sparing with tacrolimus and mycophenolate mofetil in renal transplantation.
    Borrows R; Loucaidou M; Van Tromp J; Cairns T; Griffith M; Hakim N; McLean A; Palmer A; Papalois V; Taube D
    Am J Transplant; 2004 Nov; 4(11):1845-51. PubMed ID: 15476485
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Protective effect of glucocorticoid-free immunosuppressive regimen in allogenic islet transplantation.
    Du CY; Xu EK
    Hepatobiliary Pancreat Dis Int; 2006 Feb; 5(1):43-7. PubMed ID: 16481281
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical islet transplantation in type 1 diabetes mellitus: results of Australia's first trial.
    O'Connell PJ; Hawthorne WJ; Holmes-Walker DJ; Nankivell BJ; Gunton JE; Patel AT; Walters SN; Pleass HC; Allen RD; Chapman JR
    Med J Aust; 2006 Mar; 184(5):221-5. PubMed ID: 16515432
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy and Safety of Everolimus Plus Low-Dose Tacrolimus Versus Mycophenolate Mofetil Plus Standard-Dose Tacrolimus in De Novo Renal Transplant Recipients: 12-Month Data.
    Qazi Y; Shaffer D; Kaplan B; Kim DY; Luan FL; Peddi VR; Shihab F; Tomlanovich S; Yilmaz S; McCague K; Patel D; Mulgaonkar S
    Am J Transplant; 2017 May; 17(5):1358-1369. PubMed ID: 27775865
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.